1.	A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-14, NCT01798485
2.	Crizotinib and STA-9090 in ALK Positive Lung Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-015, NCT01579994
3.	Ganetespib With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: UCL/12/0158, CMS # 1995, A15183, 2012-001598-10, TBC, NCT01590160
4.	A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-06, NCT01031225
5.	STA-9090(Ganetespib) in Metastatic Ocular Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-137, NCT01200238
6.	STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-039, NCT01551693
7.	Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-477, NCT01560416
8.	A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-09, NCT01562015
9.	A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-11, NCT01677455
10.	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-01, NCT00688116
11.	A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9090-07, NCT01183364
12.	A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI2005-11/MMRC037, NCT01485835
13.	STA9090: Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: STA 9090, NCT01554969
14.	STA-9090 in Patients With Advanced Hepatocellular Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-072, NCT01665937